Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Mammary Carcinoma, Human

Mammary Carcinoma, Human

Mammary Carcinoma is a type of breast cancer that originates in the mammary gland.
It is characterized by the abnormal growth and proliferation of cells within the breast tissue.
This condition can range from non-invasive forms, such as ductal carcinoma in situ, to invasive forms that spread to surrounding tissues and lymph nodes.
Mammary Carcinoma is a complex disease with various subtypes and genetic profiles, requiring personalized treatment approaches.
Early detection and prompt management are crucial for improving patient outcomes.
PubCompare.ai's AI-driven platform can help optimize research on Mammary Carcinoma by facilitating access to the best protocols, products, and literature, enhancing reproducibility and accuracy in the research process.

Most cited protocols related to «Mammary Carcinoma, Human»

1
Detecting Human DNA in Transplanted Mice
Cited 18 times
The presence of human-specific DNA within the blood and organs of transplanted mice was confirmed by polymerase chain reaction (PCR) amplifying an 850-bp fragment of the α-satellite region of the human chromosome 17 using primers corresponding to the primer pair 17a1/17a2 as described by Warburton et al (1991) (link). The primers were elongated to 25 nucleotides each for use at higher annealing temperatures. The sequences are shown in Table 1Oligonucleotides and probes used for PCR. For PCR, the AmpliTaq-Gold polymerase and related reagents from Perkin Elmer (Applied Biosystems GmbH, Weiterstadt, Germany) were used. The PCR reaction mixture contained 200 μM each of the respective nucleotides, 250 nM of each primer, 2 mM MgCl2, and 250 ng of genomic DNA template. Following an initial DNA denaturation and Taq activation at 94°C for 10 min, 35 1-min cycles of denaturation at 94°C and annealing/extension at 60°C were performed followed by a final elongation step at 72°C for 10 min. Amplified DNA fragments were electrophoresed through 1.75% agarose gels and subsequently visualised through ultraviolet light after staining with ethidium bromide. Genomic DNA samples from both a human breast carcinoma line (MaCa 3366) as a positive control and NOD/SCID mouse liver tissue as a negative control were processed in parallel. Routinely used PCR was evaluated by scoring band intensities expressed by one to three plus. One plus corresponded to very weak bands and three plus corresponded to very intense bands comparable to that of the positive control with 100% human cells.
Becker M., Nitsche A., Neumann C., Aumann J., Junghahn I, & Fichtner I. (2002). Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. British Journal of Cancer, 87(11), 1328-1335.
Full text: Click here
Publication 2002
BLOOD Cells Chromosomes, Human Debility DNA Denaturation Ethidium Bromide Fever Gels Genome Gold Grafts Homo sapiens Liver Maca Magnesium Chloride Mammary Carcinoma, Human Mice, Inbred NOD Mus Nucleotides Oligonucleotide Primers Polymerase Chain Reaction SCID Mice Sepharose Tissues Ultraviolet Rays
2
Microarray-Based Breast Cancer Metastasis Study
Cited 17 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Cells Crossbreeding Diagnosis DNA, Complementary Eosin Ethics Committees, Research Freezing Gene Expression Gene Expression Profiling Hematoxylin Mammary Carcinoma, Human Microarray Analysis Neoplasm Metastasis Neoplasms Nitrogen Nucleotides Oligonucleotide Primers Operative Surgical Procedures Patients Protocol Compliance Tissues Transcription, Genetic trizol
3
Metabolic Pathway Analysis of Cancer Transcriptomes
Cited 15 times
Raw counts of RNAseq analysis were obtained from TCGA data base for each cancer data set considered and analysed with the R package DESeq2 (version 1.6.3)29 , which assesses differential gene expression by use of negative binomial generalized linear model, as described by Love et al.29 The outcome of the DESeq analysis (that is, Wald test Statistics of cancer tissue vs normal tissue) was used as an estimate of differential gene expression in the subsequent pathway enrichment analysis. Every gene was associated to one or more metabolic pathways, according to the genome scale metabolic model Recon1 (ref. 30 (link)). This metabolic gene signature was then manually curated to include missing genes or functions.
Differential gene expression was corrected for promiscuity across metabolic pathways by dividing the Wald t-value statistics obtained from DESeq analysis by the number of associated pathways (promiscuity). Corrected t-values were then used as input for GSEA. GSEA was performed by applying the manually curated metabolic gene signature to promiscuity-corrected t-values according to the algorithm developed by Subramanian et al.7 (link) by using the R package ‘piano' (version 1.6.2)31 (link).
Validation of the core metabolic signature in primary cancers (Fig. 1) was performed by using gene expression data from Terunuma et al.8 (link), comprising 67 human breast cancer samples and 65 normal tissue controls. Differential gene expression analysis of breast cancer vs normal samples was performed by applying Shapiro Wilk's test for normality followed by two-sided Student's t-test and promiscuity-corrected t-values were used to perform metabolic GSEA as described above. The same approach was adopted for validation of metabolic adaptation in metastatic 786-O cell lines, compared to parental (data from Vanharanta et al.13 (link), GEO accession code: GSE32299). Metastatic and parental groups were composed of 4 and 3 samples, respectively. These and all subsequent analyses were performed in R software, version 3.1.3 (2015.03.09) ‘Smooth Sidewalk'.
Gaude E, & Frezza C. (2016). Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nature Communications, 7, 13041.
Full text: Click here
Publication 2016
Acclimatization Cell Lines Gene Expression Gene Expression Profiling Genes Genome Love Malignant Neoplasm of Breast Malignant Neoplasms Mammary Carcinoma, Human Parent Tissues
4
Profiling Breast Cancer Stem Cell miRNA
Cited 14 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Anabolism Breast Cancer Stem Cells Carcinogenesis CD44 protein, human Cells Focal Adhesions Glycogen Homo sapiens Malignant Neoplasm of Breast Malignant Neoplasms Mammary Carcinoma, Human MicroRNAs Multiplex Polymerase Chain Reaction Oligonucleotide Primers Population Group Real-Time Polymerase Chain Reaction Reverse Transcription Small Nuclear RNA Stem, Plant Stem Cells trizol
5
Breast Cancer Gene Expression Analysis
Cited 12 times
Raw data files (Affymetrix HG-U133A CEL files) of four independent human breast cancer datasets (GEO expression series GSE1456 [29 (link)], GSE3494 [28 (link)], GSE7390 [31 (link)], and GSE11121 [30 (link)]) were downloaded from the public repository GEO [33 (link)]. Each dataset was RMA-preprocessed [47 (link)] separately using the Entrez Gene-based custom CDF (version 10) from the Psychiatry/MBNI Microarray Lab at the University of Michigan ('Brainarray') [48 (link)]. Preprocessed data files of a large-scale tissue expression data set [32 (link)] were also downloaded from the same repository. The tissues included both human (GEO dataset record GDS596) and mouse (GDS592). For genes with multiple probes per Entrez gene ID, in each case, the probeset with the highest median expression value per probeset was selected as the representative probeset for that gene. To match corresponding genes across species, the HomoloGene database [33 (link)] was used.
We applied a mild variation filter using Cancer Outlier Profiler Analysis (COPA, 95th percentile) [34 (link)] to select the top 10,000 genes to be clustered in each of the human breast cancer datasets (GSE1456, GSE3494, GSE7390, GSE11121). In each dataset expression values were centered by setting the median value of each gene to zero (subtracting the gene-specific medians) and clustering analyses were performed for each dataset and species independently using hierarchical clustering with three different similarity metrics or distance metrics, respectively:
• Context-Specific Infinite Mixture Models (CSIMM) [22 (link)]. For any given pair or genes, this Bayesian method estimates the posterior pairwise probability (PPP) of the genes being co-clustered. The resulting PPP matrix is used as the similarity measure for the hierarchical clustering algorithm.
• Pearson Correlation of gene expression values as the similarity measure.
• Euclidian Distance based on per-gene normalized expression values as the distance measure.
All three hierarchical clustering algorithms used Average Linkage.
Each clustering analysis was then repeated after further variance based re-scaling each dataset by dividing expression levels by their standard deviation for each gene and each datasets separately. When computing the Pearson correlation, expression values are implicitly divided by the standard deviation. Thus, this additional normalization step did not significantly affect Pearson's correlations.
All statistical analyses were performed using the statistical programming environment R version 2.7.1 [36 ] and Bioconductor release 2.2 [37 (link)].
Freudenberg J.M., Joshi V.K., Hu Z, & Medvedovic M. (2009). CLEAN: CLustering Enrichment ANalysis. BMC Bioinformatics, 10, 234.
Full text: Click here
Publication 2009
CHOP protocol Gene Expression Genes Genetic Diversity Homo sapiens Malignant Neoplasm of Breast Malignant Neoplasms Mammary Carcinoma, Human Mice, Laboratory Microarray Analysis Tissues

Most recents protocols related to «Mammary Carcinoma, Human»

1
LXR Agonist Inhibits Breast Cancer Growth
Not available on PMC !

Example 23

We have demonstrated that LXR agonists inhibit in vitro cancer progression phenotypes in breast cancer, pancreatic cancer, and renal cancer. To investigate if LXR agonist treatment inhibits breast cancer primary tumor growth in vivo, mice injected with MDA-468 human breast cancer cells were treated with either a control diet or a diet supplemented with LXR agonist GW3965 2 (FIG. 36).

To determine the effect of orally delivered GW3965 2 on breast cancer tumor growth, 2×106 MDA-468 human breast cancer cells were resuspended in 50 μL PBS and 50 μL matrigel and the cell suspension was injected into both lower memory fat pads of 7-week-old Nod Scid gamma female mice. The mice were assigned to a control diet treatment or a GW3965-supplemented diet treatment (75 mg/kg/day) two days prior to injection of the cancer cells. The GW3965 2 drug compound was formulated in the mouse chow by Research Diets, Inc. Tumor dimensions were measured using digital calipers, and tumor volume was calculated as (small diameter)2×(large diameter)/2.

Treatment with GW3965 resulted in significant reduction in breast cancer tumor size in vivo (FIG. 36).

US11865094B2. Treatment and diagnosis of melanoma (2024-01-09). The Rockefeller University [US]. Inventors: Sohail Tavazoie [US], Nora Pencheva [US].
Full text: Click here
Patent 2024
agonists Breast Carcinoma Breast Neoplasm Cancer of Kidney Cardiac Arrest Cells Diet Disease Progression Drug Compounding Fingers Gamma Rays GW 3965 Malignant Neoplasm of Breast Malignant Neoplasms Mammary Carcinoma, Human matrigel Memory Mice, Inbred NOD Mus Neoplasms Pad, Fat Pancreatic Cancer Phenotype SCID Mice Woman
2
Combination Therapy Enhances Cancer Cell Killing
Not available on PMC !

Example 25

This experiment was to evaluate the effect of killing cancer cells by treating MDA-MB-231 cells (human breast cancer cells) with the test substance GI-101 alone or in combination with the TGF-beta signal inhibitor Vactosertib substance in an in vitro environment.

MDA-MB-231 cells were purchased from the Korea cell line bank and cultured in RPMI1640 medium (Gibco) containing 10% FBS (Gibco) and 1% antibiotic/antifungal agent (Gibco). For use in cancer cell killing test, the cells were harvested using trypsin (Gibco), and then suspended in RPMI1640 medium, and then dead cells and debris were removed using Ficoll (GE Healthcare Life Sciences) solution. The cells suspended in RPMI1640 medium were carefully layered on ficoll solution. The cell layer with a low specific gravity formed by centrifuging at room temperature at 350×g for 20 minutes was collected with a pipette, washed with PBS (Gibco), and then centrifuged at room temperature at 350×g for 5 minutes. The separated cell layer was made into a suspension of 2×105 cells/mL with FBS-free RPMI1640 medium. The cancer cell suspension was stained at 37° C. for 1 hour using CELLTRACKER™ Deep Red Dye (Thermo) in order to track proliferation or inhibition of the proliferation of cancer cells. After staining, it was centrifuged at 1300 rpm for 5 minutes, and then it was washed with FBS-free RPMI1640 medium, and then suspended in RPMI1640 medium containing 5% human AB serum (Sigma) to a concentration of 2×105 cells/mL. The cancer cell suspension was added to each well of a 96-well microplate (Corning) by 50 μl (1×104 cells), and then stabilized in an incubator (37° C., 5% CO2) for 1 hour.

Human peripheral blood mononuclear cells (PBMCs) were used in order to identify the effect of killing cancer cells by GI-101. The human PBMCs were purchased from Zen-Bio, and the PBMCs stored frozen were placed in a 37° C. water bath, and thawed as quickly as possible, and then transferred to RPMI1640 medium (Gibco) containing 10% FBS (Gibco) and 1% antibiotic/antifungal agent (Gibco), and centrifuged at 1300 rpm for 5 minutes. The separated cell layer was suspended in RPMI1640 medium, and then dead cells and debris were removed using Ficoll (GE Healthcare Life Sciences) solution in the same manner as the cancer cell line. The cells suspended in RPMI1640 medium were carefully layered on ficoll solution. The cell layer with a low specific gravity formed by centrifuging at room temperature at 350×g for 20 minutes was collected with a pipette, washed with PBS (Gibco), and then centrifuged at room temperature at 350×g for 5 minutes. The separated cell layer was suspended in RPMI1640 medium containing 5% human AB serum (Sigma) to a concentration of 5×105 cells/mL. The PBMC suspension was dispensed 50 μl into each well of a 96-well microplate (Corning) in which cancer cell line has been dispensed, depending on the conditions.

In order to identify the effect of killing the cells, a CytoTox Green reagent (INCUCYTE™ CytoTox Green, Satorius) that binds to the DNA of cells to be killed was prepared in 1 μl per 1 mL of RPMI1640 medium containing 5% human AB serum (Sigma). The prepared medium was used for dilution of the test substance, and the effect of killing the cells could be quantitatively identified by staining the cells to be killed when the test substance was co-cultured with cancer cell lines and PBMCs.

Vactosertib power was dissolved in DMSO (Sigma) to a concentration of 48.4 mM, and diluted using RPMI1640 medium containing a CytoTox Green reagent, and then used in the experiment at a final concentration of 12.1 nM (50 μL) per well of a 96-well microplate.

GI-101 was diluted by ⅓ using RPMI1640 medium containing a CytoTox Green reagent, and then used in the experiment at final concentrations of 0.4 nM, 1.2 nM, 3.7 nM, 11.1 nM, 33.3 nM, and 100 nM by 50 μl per well of a 96-well microplate.

The prepared test substance was placed in each well of a 96-well microplate in which cancer cell lines and PBMCs were dispensed depending on the conditions, and cultured in an incubator (37° C., 5% CO2) for 24 hours, and the proliferation or death of cancer cells was observed through the real-time cell imaging analysis equipment IncuCyte S3 (Satorious). The death of cancer cells was quantified by the integrated intensity of the cells stained in green with a CytoTox Green reagent.

As a result, it was identified that the group having received a combination of GI-101 and Vactosertib exhibited the excellent effect of killing cancer cells as compared with the group having received each drug alone.

US11857601B2. Pharmaceutical composition for cancer treatment comprising fusion protein including IL-2 protein and CD80 protein and anticancer drug (2024-01-02). GI INNOVATION, INC. [KR]. Inventors: Myung Ho Jang [KR], Su Youn Nam [KR], Young Jun Koh [KR].
Full text: Click here
Patent 2024
A-101 Antibiotics Antifungal Agents Bath Cell Death Cell Lines Cell Proliferation Cells Ficoll Freezing Gastrointestinal Cancer Homo sapiens Malignant Neoplasms Mammary Carcinoma, Human MCF-7 Cells MDA-MB-231 Cells PBMC Peripheral Blood Mononuclear Cells PER1 protein, human Pharmaceutical Preparations Psychological Inhibition Serum Sulfoxide, Dimethyl Technique, Dilution Transforming Growth Factor beta Trypsin vactosertib
3
Evaluation of MPV.10.34.d IRC Effectiveness
Not available on PMC !

Example 11

MPV.10.34.d IRC Effectiveness in Human Assays

While the in vitro functional test results of the above experiments were promising, the next desired step in the analysis was to perform similar experiments in human-based assays. To this end, the response of mock human cellular immune system components to tumor cells exposed to MPV.10.34.d IRC was examined in vitro. Human CMV (HCMV) was selected for this study since human CMV is highly prevalent (infecting 50-90% of the human population) and mostly asymptomatic in healthy individuals. (See, Longmate et al., Immunogenetics, 52(3-4):165-73, 2001; Pardieck et al., F1000Res, 7, 2018; and van den Berg et al., Med. Microbiol. Immunol., 208(3-4):365-373, 2019). Importantly, HCMV establishes a life-long persistent infection that requires long-lived cellular immunity to prevent disease. Hence, it is rational to hypothesize that a complex adaptive cell-mediated anti-viral immunity developed over many years to strongly control a viral infection in an aging person can be repurposed and harnessed to treat cancer.

In these experiments, CD8+ T cell responses to CMV peptides were tested in three different human tumor cell lines, including HCT116, OVCAR3, and MCF7. All three of these human tumor cell lines are HLA-A*0201 positive.

In vitro cytotoxicity assays. HTC112, human colon cancer cells, MCF7, human breast cancer cells, and OVCAR3, human ovarian cancer cells (all from ATCC, Manassas, VA, US) were seeded overnight at 0.01 to 0.2×106 per well per 100 μL per 96 well plate. The next day (about 20 to 22 hrs later), each cell line was incubated for one hour at 37° C. under the following conditions: (1) CMV peptide at a final concentration of 1 μg/mL (positive control), (2) MPV.10.34.d at a final concentration of 2.5 μg/mL (negative control), (3) CMV-conjugated MPV.10.34.d IRC at a final concentration of 2.5 μg/mL, (4) CMV-conjugated HPV16 IRC at a final concentration of 2.5 μg/mL, and (5) no antigen (negative control). After 1 hour, the cells were washed vigorously with 200 μL of media for three times to remove non-specific binding. Human patient donor CMV T cells (ASTARTE Biologics, Seattle, WA, US) were added at the E:T (effector cell:target cell) ratio of 10:1 and incubated in a tissue culture incubator for 24 hrs at 37 C, 5% CO2. The total final volume of each sample after co-culture was 200 μL. Cell viability was measured after co-culturing. Cell viability was measured with CELLTITER-GLO® (Promega, Madison, WI, US). This assay provides a luciferase-expressing chemical probe that detects and binds to ATP, a marker of cell viability. The amount of ATP generated from tumor cells was quantified according to manufacturer protocols. In these assays, reduced luciferase activity indicates cell death and suggests greater immune redirection and greater cytotoxicity.

The results are provided in FIG. 25. CMV-conjugated MPV.10.34.d IRC (“VERI-101” in FIGS. 25A, 25B, and 25C) was equally effective as CMV-conjugated HPV16 IRC (“CMV AIR-VLP” in FIGS. 25A, 25B, and 25C) in redirecting human healthy donor CMV pp65-specific CD8+ T-cells (Astarte Biologics, Inc., Bothell, WA, US) to kill immortalized HLA.A2 positive human colon cancer cells (HCT116), human ovarian cancer cells (OVCAR3), and human breast cancer cells (MCF7). The control samples (“No Ag” or “VERI-000” in FIGS. 25A, 25B, and 25C) showed no background tumor killing. Together, these data demonstrate that MPV.10.34.d IRC redirects mouse and human immune responses against tumor cells in vitro.

US11858964B2. Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer (2024-01-02). VerImmune Inc. [US]. Inventors: Joshua Weiyuan Wang [US], Ken Matsui [US], Philip Alan Storm [US], Kristin Marie Peters [US].
Full text: Click here
Patent 2024
Acclimatization Antigens Antiviral Agents Biological Assay Biological Factors Cancer of Colon CD8-Positive T-Lymphocytes Cell Death Cell Line, Tumor Cell Lines Cells Cell Survival Cellular Immune Response Cellular Immunity Cytotoxin Figs HLA-A2 Antigen Homo sapiens Human papillomavirus 16 In Vitro Testing Luciferases Malignant Neoplasms Mammary Carcinoma, Human MCF-7 Cells Mus Neoplasms Ovarian Cancer Patients Peptides Persistent Infection Promega Response, Immune Response Elements System, Immune T-Lymphocyte Tissue Donors Tissues UL83 protein, Human herpesvirus 5 Virus Virus Diseases
4
Lentiviral Knockdown of LINC01614
Not available on PMC !

Example 3

MDA-MB-231 and Hs578T cells were prepared and inoculated to a 6-pore plate with a density of 2.5×105 cells/pore. When the cells density reached 70%, add sh-LINC01614-1, sh-LINC01614-2 or sh-Control lentivirus (MOI=10) supernatant to the cell and transduce for 24 hour. Remove and discard the lentivirus-containing transduction medium and replace with fresh growth medium. Continue to incubate the cells for 72 hours. After 72 h, the GFP expression was analysis by a fluorescence microscope. When the expression reached more than 90% indicated a successful transfection.

US11873492B2. Medication and diagnostic kit for inhibiting metastasis and invasion of breast cancer, shRNA molecule for silencing expression of human LINC01614 and application thereof (2024-01-16). Zhejiang Chinese Medical University [CN]. Inventors: Fangfang Tao [CN], Zhiqian Zhang [CN], Wenhong Liu [CN], Ye Xu [CN], Qingling Liu [CN], Junfeng Li [CN].
Full text: Click here
Patent 2024
Culture Media Lentivirus Mammary Carcinoma, Human Microscopy, Fluorescence Transfection
5
Generating PIAS-Knockout Cell Lines
Human breast cancer cell
line MDA-MB-231 was purchased from American Type Culture Collection
(ATCC), and HEK293 stably expressing the 6xHis-SUMO3-Q87R/Q88N mutant
(HEK293-SUMO3m)23 (link) was cultured in Dulbecco’s
modified Eagle’s medium (HyClone) supplemented with 10% fetal
bovine serum (Wisent), 1% l-glutamine (Thermo Fisher Scientific),
and 1% penicillin/streptomycin (Invitrogen) in 5% CO2 at
37 °C.
For gene knockout, the CRISPR/Cas9-based gene knockout
vectors pCRISPR were purchased from Genecopoeia, Inc. (Rockville,
MD). We ordered three different sgRNAs for each PIAS gene. The sgRNA
sequence for each gene is listed below. PIAS1-sgRNA1: 5′-TTCTGAACTCCAAGTACTGT-3′,
PIAS1-sgRNA2: 5′- GCCCTGCATTTGCTAAAGGC-3′, PIAS1-sgRNA3:
5′- ACTTGAATGTACGTTGGGGA-3′, PIAS2-sgRNA1: 5′-CAAGTATTACTAGGCTTTGC-3′,
PIAS2-sgRNA2: 5′-ATAAATGCAGCGCCCTCATC-3′, PIAS2-sgRNA3:
5′-CTCATCAAGCCCACGAGTTT-3′, PIAS3-sgRNA1: 5′-GCCCTTCTATGAAGTCTATG-3′,
PIAS3-sgRNA2: 5′- ATGGTGACATCAGGGTGCAC-3′, PIAS3-sgRNA3:
5′-GCCCTTCTATGAAGTCTATG-3′, PIAS4-sgRNA1: 5′-GGCTTCGCGCCGTAGTCTTAG-3′,
PIAS4-sgRNA2: 5′- GAAGCACGAGCTCGTCACCA-3′, PIAS4-sgRNA3:
5′-GAGCTTCACC AGGCGGACTTC-3′, and scrambled sgRNA: 5′-GGCTTCGCGCCGTAGTCTTA-3′.
MDA-MB-231 cells or HEK293-SUMO3m cells were transfected with 1 μg
of pCRISPR vector or a scrambled sgRNA vector as negative control
per million cells using JetPrime Reagent (Polyplus-transfection) according
to the manufacturer’s protocol. Single-cell sorting for clonal
cell line development was achieved by fluorescence-activated cell
sorting (FACS) based on Red Fluorescent Proteins-mCherry signals 48
h after transfection. mCherry-positive cells were cultured and expanded
for 2 weeks. PIAS knockout efficiency was confirmed by western blotting.
Li C., Boutet A., Pascariu C.M., Nelson T., Courcelles M., Wu Z., Comtois-Marotte S., Emery G, & Thibault P. (2023). SUMO Proteomics Analyses Identify Protein Inhibitor of Activated STAT-Mediated Regulatory Networks Involved in Cell Cycle and Cell Proliferation. Journal of Proteome Research, 22(3), 812-825.
Publication 2023
Cells Cloning Vectors Clustered Regularly Interspaced Short Palindromic Repeats Culture Media Eagle Fluorescence Gene Knockout Techniques Genes Glutamine HEK293 Cells IAP protocol Mammary Carcinoma, Human mCherry fluorescent protein MDA-MB-231 Cells Penicillins PIAS1 protein, human PIAS3 protein, human Serum Streptomycin Transfection

Top products related to «Mammary Carcinoma, Human»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Mcf 7 by American Type Culture Collection
Sourced in United States, United Kingdom, China, Germany, France, Japan, Italy, Switzerland, Sweden, India, Canada, Egypt, Australia, Holy See (Vatican City State), Brazil
MCF-7 is a cell line derived from human breast adenocarcinoma. It is an adherent epithelial cell line that can be used for in vitro studies.
3
Mda mb 231 by American Type Culture Collection
Sourced in United States, United Kingdom, Germany, China, Japan, France, Australia, Italy, India, Switzerland, Brazil, Canada, Holy See (Vatican City State)
MDA-MB-231 is a cell line derived from a human breast adenocarcinoma. This cell line is commonly used in cancer research and is known for its aggressive and metastatic properties.
4
Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica
DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.
5
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
6
Streptomycin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
7
Penicillin by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
8
Rpmi 1640 medium by Thermo Fisher Scientific
Sourced in United States, China, Germany, United Kingdom, Japan, France, Canada, Australia, Italy, Switzerland, Belgium, New Zealand, Spain, Israel, Sweden, Denmark, Macao, Brazil, Ireland, India, Austria, Netherlands, Holy See (Vatican City State), Poland, Norway, Cameroon, Hong Kong, Morocco, Singapore, Thailand, Argentina, Taiwan, Province of China, Palestine, State of, Finland, Colombia, United Arab Emirates
RPMI 1640 medium is a commonly used cell culture medium developed at Roswell Park Memorial Institute. It is a balanced salt solution that provides essential nutrients, vitamins, and amino acids to support the growth and maintenance of a variety of cell types in vitro.
9
Fetal bovine serum (fbs) by Merck Group
Sourced in United States, Germany, United Kingdom, Japan, Italy, China, Macao, Switzerland, France, Canada, Sao Tome and Principe, Spain, Australia, Ireland, Poland, Belgium, Denmark, India, Sweden, Israel, Austria, Brazil, Czechia, Netherlands, Portugal, Norway, Holy See (Vatican City State), New Zealand, Hungary, Senegal, Argentina, Thailand, Singapore, Ukraine, Mexico
FBS, or Fetal Bovine Serum, is a commonly used cell culture supplement. It is derived from the blood of bovine fetuses and provides essential growth factors, hormones, and other nutrients to support the growth and proliferation of a wide range of cell types in vitro.
10
Rpmi 1640 by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, France, Canada, Japan, Australia, Italy, Switzerland, Belgium, New Zealand, Austria, Netherlands, Israel, Sweden, Denmark, India, Ireland, Spain, Brazil, Norway, Argentina, Macao, Poland, Holy See (Vatican City State), Mexico, Hong Kong, Portugal, Cameroon
RPMI 1640 is a common cell culture medium used for the in vitro cultivation of a variety of cells, including human and animal cells. It provides a balanced salt solution and a source of essential nutrients and growth factors to support cell growth and proliferation.

More about "Mammary Carcinoma, Human"

Mammary Carcinoma, also known as Breast Cancer, is a complex and multifaceted disease that originates in the mammary gland.
This condition is characterized by the abnormal proliferation and growth of cells within the breast tissue, ranging from non-invasive forms like Ductal Carcinoma in Situ (DCIS) to invasive types that can spread to surrounding tissues and lymph nodes.
Mammary Carcinoma has various subtypes, each with unique genetic profiles, requiring personalized treatment approaches.
Understanding the underlying mechanisms and molecular characteristics of Mammary Carcinoma is crucial for developing effective therapeutic strategies.
Cell lines like MCF-7 and MDA-MB-231, commonly used in Mammary Carcinoma research, provide valuable insights into the disease.
These cell lines are typically cultured in media such as DMEM, RPMI 1640, and supplemented with antibiotics like Penicillin and Streptomycin to maintain optimal growth conditions.
Early detection and prompt management of Mammary Carcinoma are essential for improving patient outcomes.
PubCompare.ai's AI-driven platform can help optimize Mammary Carcinoma research by facilitating access to the best protocols, products, and literature, enhancing reproducibility and accuracy in the research process.
This can lead to a deeper understanding of the disease and ultimately, more effective treatments for patients.